Answers are grounded in this paper and cite their sources.
Objective To assess the real‐world long‐term treatment effectiveness of ixekizumab (IXE) in Chinese patients with moderate‐to‐severe psoriasis (msPsO). Methods This study used a Chinese national psoriasis registry database to retrospectively analyze data on patients initiating IXE treatment between 2020 and 2024. Baseline patient characteristics, treatment information, and treatment responses at Weeks 24, 48, 60, and 104 were extracted for data analysis. Descriptive statistics were used to summarize the baseline patient characteristics and treatment responses based on measures such as the Psoriasis Area and Severity Index (PASI). Multiple logistic regression analyses were conducted to explore associations between patient characteristics and PASI response outcomes, including PASI 75, PASI 90, and PASI 100, at each time point. Results A total of 415 msPsO patients from 44 hospitals were included (mean age ± standard deviation [SD]: 43.0 ± 14.8 years, male: 72.5%, overweight/obesity: 45.5%, and severe psoriasis: 83.9%). IXE showed sustained effectiveness across all four prespecified time points: PASI 75 response rates were 86.2% at Week 24 ( N = 311), 83.7% at Week 48 ( N = 178), 85.3% at Week 60 ( N = 136), and 87.1% at Week 104 ( N = 70); PASI 90 response rates were 74.3%, 71.9%, 71.3%, and 67.1%, respectively; and PASI 100 response rates were 58.5%, 57.9%, 56.6%, and 47.1%, respectively. Multiple logistic regression analyses showed that overweight/obesity (48‐week PASI 75: odds ratio [OR] = 0.313, p = 0.047), prior biologic therapy (48‐week PASI 75: OR = 0.045, p = 0.010; 60‐week PASI 75: OR = 0.046, p = 0.014), and urban employee basic medical insurance (48‐week PASI 75: OR = 4.263, p = 0.011; 48‐week PASI 90: OR = 2.841, p = 0.016; 60‐week PASI 90: OR = 2.597, p = 0.042; 60‐week PASI 100: OR = 2.384, p = 0.047) were significantly associated with PASI responses. At Week 104, no significant association was found between the baseline characteristics and PASI responses. Conclusion This real‐world study showed sustained reduction in psoriasis severity in the long term among IXE‐treated Chinese patients with msPsO, mirroring clinical trials.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: